DK2297106T3 - Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande - Google Patents
Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstandeInfo
- Publication number
- DK2297106T3 DK2297106T3 DK09754139.5T DK09754139T DK2297106T3 DK 2297106 T3 DK2297106 T3 DK 2297106T3 DK 09754139 T DK09754139 T DK 09754139T DK 2297106 T3 DK2297106 T3 DK 2297106T3
- Authority
- DK
- Denmark
- Prior art keywords
- pde4
- treatment
- mediated diseases
- phenoxypyridinylamide
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12893908P | 2008-05-27 | 2008-05-27 | |
| PCT/GB2009/050566 WO2009144494A1 (en) | 2008-05-27 | 2009-05-26 | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2297106T3 true DK2297106T3 (da) | 2014-10-06 |
Family
ID=40821676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09754139.5T DK2297106T3 (da) | 2008-05-27 | 2009-05-26 | Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8273774B2 (enExample) |
| EP (2) | EP2297106B1 (enExample) |
| JP (1) | JP5607032B2 (enExample) |
| KR (1) | KR101605576B1 (enExample) |
| CN (1) | CN102105448B (enExample) |
| AR (1) | AR071920A1 (enExample) |
| AU (1) | AU2009252938B2 (enExample) |
| BR (1) | BRPI0912103A2 (enExample) |
| CA (1) | CA2721065C (enExample) |
| CL (1) | CL2009001298A1 (enExample) |
| CY (1) | CY1115566T1 (enExample) |
| DK (1) | DK2297106T3 (enExample) |
| ES (1) | ES2502527T3 (enExample) |
| HK (1) | HK1203482A1 (enExample) |
| HR (1) | HRP20140884T1 (enExample) |
| MX (1) | MX2010012492A (enExample) |
| PE (1) | PE20100144A1 (enExample) |
| PL (1) | PL2297106T3 (enExample) |
| PT (1) | PT2297106E (enExample) |
| RU (1) | RU2509077C2 (enExample) |
| SI (1) | SI2297106T1 (enExample) |
| TW (1) | TW200951139A (enExample) |
| UY (1) | UY31849A (enExample) |
| WO (1) | WO2009144494A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102460165B (zh) * | 2009-05-19 | 2016-08-17 | 维维雅生物技术公司 | 用于为血液肿瘤提供离体个体化药物测试的方法 |
| WO2013067379A1 (en) * | 2011-11-04 | 2013-05-10 | Oregon Health & Science University | Pharmaceutical compositions comprising napthamides |
| EP3190891B1 (en) * | 2014-09-10 | 2020-01-15 | Epizyme, Inc. | Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| HUE048658T2 (hu) * | 2016-02-23 | 2020-07-28 | Pfizer | 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazin-2-karboxamid vegyületek |
| ES2987852T3 (es) | 2018-09-10 | 2024-11-18 | Kaken Pharma Co Ltd | Novedoso derivado de amida heteroaromática y medicamento que lo contiene |
| US12240855B2 (en) | 2019-03-06 | 2025-03-04 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
| KR102271305B1 (ko) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272907B1 (ko) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272910B1 (ko) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR20220140960A (ko) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR20220146095A (ko) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
| KR102311224B1 (ko) | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| EP0260817B1 (en) | 1986-08-21 | 1991-05-15 | Pfizer Inc. | Quinazolinediones and pyridopyrimidinediones |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US5264437A (en) | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| KR20000068711A (ko) | 1997-08-06 | 2000-11-25 | 도리이 신이치로 | Ⅳ형 포스포디에스테라제 억제제로서의 1-아릴-1,8-나프틸리딘-4-온 유도체 |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU780284B2 (en) | 1999-02-02 | 2005-03-10 | 4-Aza Bioscience Nv | Immunosurpressive effects of pteridine derivatives |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| AU2001266233B2 (en) | 2000-07-07 | 2006-06-29 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
| CN1302007C (zh) | 2001-04-30 | 2007-02-28 | 葛兰素集团有限公司 | 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物 |
| EP1397359B1 (en) | 2001-05-24 | 2005-08-31 | Merck Frosst Canada & Co. | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2003068233A1 (en) * | 2002-02-11 | 2003-08-21 | Pfizer Limited | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases |
| CN1652782A (zh) * | 2002-02-11 | 2005-08-10 | 美国辉瑞有限公司 | 用作pde4抑制剂的烟酰胺衍生物 |
| DE10216339A1 (de) | 2002-04-13 | 2003-10-23 | Boehringer Ingelheim Pharma | Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EA200500618A1 (ru) | 2002-10-11 | 2005-12-29 | Пфайзер Инк. | Производные индола в качестве бета-2 агонистов |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US6909002B2 (en) * | 2002-11-22 | 2005-06-21 | Merck & Co., Inc. | Method of preparing inhibitors of phosphodiesterase-4 |
| US20060040981A1 (en) | 2002-11-22 | 2006-02-23 | Daniel Dube | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| IS7839A (is) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
| US20060258668A1 (en) | 2003-05-29 | 2006-11-16 | Scolnick Edward M | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders |
| GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| US7153870B2 (en) * | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317471D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
| GB0317509D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| CA2533786A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| WO2005013993A1 (en) * | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| AP2006003534A0 (en) * | 2003-09-03 | 2006-04-30 | Pfizer | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. |
| US20090246281A1 (en) | 2003-11-03 | 2009-10-01 | Norton Healthcare Ltd. | Soft steroid compositions for use in dry powder inhalers |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| KR20070068432A (ko) | 2004-10-29 | 2007-06-29 | 아스트라제네카 아베 | 염증 질환의 치료를 위한 글루코코르티코이드 수용체조절제로서의 신규 술폰아미드 유도체 |
| WO2007050576A2 (en) | 2005-10-27 | 2007-05-03 | Merck & Co., Inc. | A method of preparing a 4-oxo-1- (3 substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3- carboxamide phosphodiesterase-4 inhibitor |
| WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
-
2009
- 2009-05-26 AU AU2009252938A patent/AU2009252938B2/en not_active Ceased
- 2009-05-26 CN CN2009801293473A patent/CN102105448B/zh not_active Expired - Fee Related
- 2009-05-26 CA CA2721065A patent/CA2721065C/en not_active Expired - Fee Related
- 2009-05-26 JP JP2011511094A patent/JP5607032B2/ja not_active Expired - Fee Related
- 2009-05-26 ES ES09754139.5T patent/ES2502527T3/es active Active
- 2009-05-26 HR HRP20140884AT patent/HRP20140884T1/hr unknown
- 2009-05-26 BR BRPI0912103-0A patent/BRPI0912103A2/pt not_active Application Discontinuation
- 2009-05-26 KR KR1020107026555A patent/KR101605576B1/ko not_active Expired - Fee Related
- 2009-05-26 EP EP09754139.5A patent/EP2297106B1/en not_active Not-in-force
- 2009-05-26 SI SI200930997T patent/SI2297106T1/sl unknown
- 2009-05-26 US US12/471,599 patent/US8273774B2/en not_active Expired - Fee Related
- 2009-05-26 RU RU2010149496/04A patent/RU2509077C2/ru active
- 2009-05-26 PL PL09754139T patent/PL2297106T3/pl unknown
- 2009-05-26 DK DK09754139.5T patent/DK2297106T3/da active
- 2009-05-26 MX MX2010012492A patent/MX2010012492A/es active IP Right Grant
- 2009-05-26 TW TW098117462A patent/TW200951139A/zh unknown
- 2009-05-26 EP EP14171857.7A patent/EP2778156B8/en not_active Not-in-force
- 2009-05-26 WO PCT/GB2009/050566 patent/WO2009144494A1/en not_active Ceased
- 2009-05-26 PT PT97541395T patent/PT2297106E/pt unknown
- 2009-05-27 UY UY0001031849A patent/UY31849A/es unknown
- 2009-05-27 CL CL2009001298A patent/CL2009001298A1/es unknown
- 2009-05-27 PE PE2009000741A patent/PE20100144A1/es not_active Application Discontinuation
- 2009-05-27 AR ARP090101896A patent/AR071920A1/es unknown
-
2011
- 2011-09-07 HK HK15102697.5A patent/HK1203482A1/en unknown
-
2014
- 2014-09-17 CY CY20141100759T patent/CY1115566T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2297106T3 (da) | Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande | |
| DK2245199T3 (da) | Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande | |
| DK2350416T4 (da) | Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude | |
| DK2483278T3 (da) | Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer | |
| DK2480574T3 (da) | Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme | |
| DK2114419T3 (da) | Natriummetaarsenit til anvendelse i behandling af smerte og inflammation | |
| DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
| DK2579877T3 (da) | Morpholinopyrimidiner og deres anvendelse til terapi | |
| DK2222675T3 (da) | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse | |
| DK1917246T3 (da) | Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme | |
| BRPI0810481A2 (pt) | Novas asparaginases e usos destas | |
| DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
| DK2322221T3 (da) | Farmaceutisk sammensætning til behandling og forebyggelse af cancer | |
| DK3460056T3 (da) | Terapeutiske nukleasesammensætninger og fremgangsmåder | |
| DK2342233T3 (da) | Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer | |
| BRPI1013640A2 (pt) | composicao farmaceutica, metodos para o tratamento e usos dos mesmos | |
| DK3150240T3 (da) | Systemer og fremgangsmåder til fremføring af terapeutiske midler | |
| DK2437762T3 (da) | Kunstige tårer og terapeutiske anvendelser | |
| DK2234985T3 (da) | 4-(4-cyano-2-thioaryl)-dihydropyrimidinoner og deres anvendelse | |
| DK2473510T3 (da) | Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer | |
| DK2475372T4 (da) | Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse | |
| DK3067066T3 (da) | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom | |
| SI2894165T1 (sl) | Postopki in sestavki za zdravljenje motenj povezanih s komplementom | |
| DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
| DK2389352T3 (da) | Arginaseinhibitorer og anvendelsesfremgangsmåder |